Application of improved glomerular filtration rate estimation by a neural network model in patients with neurogenic lower urinary tract dysfunction
CONCLUSION: The MLP-based model offered significant advantages in estimating GFR in Chinese NLUTD patients, and its application could be suggested in clinical practice.PMID:38629744 | DOI:10.5414/CN111150 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 17, 2024 Category: Urology & Nephrology Authors: Ying-Chun Ma Yang Xie Limin Liao Source Type: research
Physical functional capacity assessment in children with chronic kidney disease: A cross sectional observational study
CONCLUSION: Muscle strength and functional capacity were most impaired in Indian children on hemodialysis and best preserved in KTR.PMID:38629745 | DOI:10.5414/CN111295 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 17, 2024 Category: Urology & Nephrology Authors: Himani Goswami Harda Shah Kinnari Vala Shahenaz Kapadia Bharat Tiwari Anshuman Saha Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria
CONCLUSION: ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.PMID:38606848 | DOI:10.5414/CN111247 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Kittiphan Chienwichai Phirada Chaloemwa Sorawat Sangkaew Arunchai Chang Source Type: research
Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial
CONCLUSION: Cyclophosphamide combined with glucocorticoid therapy is effective for improving the overall remission rate and can suppress inflammatory responses and oxidative stress in patients with idiopathic membranous nephropathy.PMID:38606849 | DOI:10.5414/CN111287 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 12, 2024 Category: Urology & Nephrology Authors: Jianlin Wang Dong Bian Jian Sun Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
